Controlling Inflammation Due to Cardiac Devices

控制心脏装置引起的炎症

基本信息

批准号：
7800849
负责人：
Rekha Bansal
金额：
$ 42.02万
依托单位：
NOVELMED THERAPEUTICS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-05-01 至 2011-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7800849
关键词：
Affinity Affinity Chromatography Aliquot Alternative Complement Pathway Animal Model Animals Anti-Inflammatory Agents Anti-inflammatory Antibodies Antibody Formation Aorta Applications Grants Arteries Arthritis Binding Biocompatible Materials Biological Assay Blood Blood Circulation Blood Platelets Blood specimen Bolus Infusion Brain Injuries Bypass Cardiac Cardiac Surgery procedures Cardiopulmonary Bypass Cells Cessation of life Chemistry Chest Clinical Coagulation Process Complement Complement 3a Complement 5a Complement Activation Congenital Heart Defects Contracts Coronary Angiography Cytolysis Data Devices Disease Dose Drug Compounding Drug Kinetics Elastases Endothelium Engineering Ensure Enzyme-Linked Immunosorbent Assay Enzymes Equipment Evaluation Event Extracorporeal Circulation FDA approved Fund Raising Heart Heart Transplantation Heart Valves Heart-Lung Machine Hemorrhage Hemostatic function Hour Human Human Anti-Mouse Antibody Humira IgG2 Immune response Immunoglobulin Constant Region Immunoglobulin Variable Region In Vitro Inflammation Inflammation Mediators Inflammatory Inflammatory Response Injury Integrins Intellectual Property Interleukin-1 Intravenous Investigational Drugs Kidney Laboratories Lawyers Lead Legal patent Leukocytes Lilly brand of abciximab Liquid substance Liver Lucentis Lung Macular degeneration Magnetic Resonance Imaging Measurement Measures Mediating Methods Modeling Monitor Monoclonal Antibodies Mus Neutropenia Neutrophil Activation Operative Surgical Procedures Organ Organ failure Oryctolagus cuniculus Oxidative Stress Pathology Patients Percutaneous Transluminal Coronary Angioplasty Peroxides Pharmaceutical Preparations Pharmacodynamics Pharmacologic Substance Phase Pichia Plasma Plasma Cells Platelet Activation Preparation Procedures Process Production Properdin Proteins Protocols documentation Receptor Cell Regulatory Affairs Reporting Rest Right atrial structure Rivers Roche brand of rituximab Rodent Role Rotation Running Safety Sales Scientist Secure Serum Solid Surface Surgeon TNF gene Testing Therapeutic Therapeutic Monoclonal Antibodies Therapeutic Uses Thrombocytopenia Tissues Toxic effect Trauma Troponin T Tumor Necrosis Factor-alpha Vascular Endothelial Growth Factors Whole Blood Work ascending aorta base blood treatment chimeric antibody cross reactivity cytokine drug candidate efficacy testing human TNF protein human tissue immunogenicity improved in vivo in vivo Model infliximab meetings monocyte neutralizing monoclonal antibodies neutrophil nonhuman primate prevent public health relevance research study residence soluble complement C5b-9 technology development valve replacement

项目摘要

DESCRIPTION (provided by applicant): NovelMed's lead drug candidate prevents biomaterials induced cellular activation. Activated cells release inflammatory mediators that are responsible for pathological trauma that leads to cardiac, lung, liver, and brain injuries during surgical procedures that require cardiac devices. Our findings provide convincing support for developing YalcixiMab as a treatment to prevent biomaterial-induced inflammation that occurs during surgical procedures. CPB circuits are used during various procedures for heart transplant, and valve replacements. Treatment of blood with YalcioMab prior to the extracorporeal circulation prevents complement activation, neutrophil activation, monocyte activation, platelet activation and the formation of leukocyte-platelet aggregates. The drug also prevents the release of potent inflammatory mediators such as TNF-1. . PUBLIC HEALTH RELEVANCE: NovelMed is developing treatments that will reduce/prevent complications that arise when blood is exposed to biomaterial surfaces of the cardiac devices. Cardiopulmonary bypass circuits are utilized in several cardiac surgeries as a heart-lung machine while surgeons perform procedures on the empty heart. The ultimate objective of this proposal is the development of technologies that will improve the manufacturing of engineered human tissues

描述（由申请人提供）：Novelmed的铅候选药物可防止生物材料诱导的细胞激活。活化细胞释放炎症介质，导致病理创伤，导致需要心脏器件的手术过程中导致心脏，肺，肝脏和脑损伤。我们的发现为开发YALCIXIMAB作为一种治疗方法提供了令人信服的支持，以防止在手术过程中发生生物材料引起的炎症。 CPB电路在各种过程中用于心脏移植和更换瓣膜。在体外循环之前，用YALCIOMAB治疗血液可以防止补体激活，中性粒细胞活化，单核细胞激活，血小板激活和白细胞 - 植物 - 植物 - 平台 - 骨骼聚集体的形成。该药物还防止了有效的炎症介质（如TNF-1）的释放。。公共卫生相关性：新颖的是正在开发治疗方法，以减少/预防血液暴露于心脏器件的生物材料表面时出现的并发症。在多次心脏手术中使用心肺旁路电路作为心脏肺机，而外科医生在空心的心脏上执行程序。该提案的最终目标是开发技术，这些技术将改善工程人类组织的制造